Revance Therapeutics (NASDAQ:RVNC) Announces Quarterly Earnings Results

Revance Therapeutics (NASDAQ:RVNC) issued its earnings results on Sunday. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.01, MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.

RVNC traded down $1.10 during midday trading on Tuesday, reaching $25.86. The company’s stock had a trading volume of 45,639 shares, compared to its average volume of 425,713. The stock has a market cap of $1.72 billion, a P/E ratio of -5.70 and a beta of 1.42. The company has a fifty day simple moving average of $28.31 and a 200 day simple moving average of $26.92. The company has a current ratio of 7.07, a quick ratio of 7.01 and a debt-to-equity ratio of 0.48. Revance Therapeutics has a twelve month low of $11.78 and a twelve month high of $34.62.

In other Revance Therapeutics news, insider Aubrey Rankin sold 33,119 shares of the firm’s stock in a transaction that occurred on Monday, February 1st. The stock was sold at an average price of $25.95, for a total value of $859,438.05. Following the completion of the sale, the insider now owns 67,871 shares in the company, valued at approximately $1,761,252.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.80% of the company’s stock.

Several research analysts have weighed in on the company. Mizuho upped their target price on Revance Therapeutics from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays increased their price objective on Revance Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Monday, October 26th. Zacks Investment Research lowered Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 12th. Needham & Company LLC increased their price objective on Revance Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday, January 8th. Finally, HC Wainwright increased their price objective on Revance Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Revance Therapeutics currently has an average rating of “Buy” and a consensus target price of $32.88.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.

Featured Article: Outperform Rating

Earnings History for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.